Key result
A 43-year-old male developed neuroleptic malignant syndrome, characterized by hyperpyrexia, muscle rigidity, and elevated CPK, while receiving a combination of carbamazepine and amitriptyline.
Case Report (n=1)
No
This case report highlights that non-antipsychotic medications such as carbamazepine and amitriptyline can trigger neuroleptic malignant syndrome, necessitating prompt recognition and withdrawal of the offending agents.
May signal rare NMS risk with carbamazepine-amitriptyline; case report leaves association open for confirmation.
Neuroleptic malignant syndrome (NMS) is an infrequent, but potentially life-threatening neurologic emergency associated with the use of neuroleptic or antipsychotic drugs. A 43 years old male with a history of trigeminal neuralgia developed Neuroleptic malignant syndrome while receiving Carbamazepine and Amitryptylline. Treatment is mainly supportive and includes withdrawal of the neuroleptic medication and, possibly, administration of drugs such as dantrolene and bromocriptine. Complications of NMS include acute renal failure and acute respiratory failure. The possible etiologies, triggering factors and treatment are discussed with reference to existing literature.
No takes yet. Share an insight, caveat, or question.
P. et al. (2021) conducted a case report in Neuroleptic malignant syndrome (n=1). Carbamazepine and Amitriptyline was evaluated on Development of Neuroleptic Malignant Syndrome. A 43-year-old male developed neuroleptic malignant syndrome, characterized by hyperpyrexia, muscle rigidity, and elevated CPK, while receiving a combination of carbamazepine and amitriptyline.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: